
CRAZY !
An update on where big pharma's licensing money is getting spent. (China)


CRAZY !
An update on where big pharma's licensing money is getting spent. (China)

Ok.. that’s confidence.
SHE RAISED GUIDANCE FOR NEXT YEAR. Colette just dunked on the Nvidia bears from the foul line. "We are raising our fiscal year 2028 outlook. We expect revenue to grow approximately 75% year over year, up from 70%, and off what is now a higher fiscal 2027 base" $NVDA

$VKTX Obesity Week 2026 Analyst Day Presentation November 13, 2026 ir.vikingtherapeutics.com/we…

$PEPG decimation post BIC splicing data.

*Up to $5.9B (no upfront disclosed).
Eli Lilly continues to be pharma’s biggest shopaholic. more on Stipple Bio's up to $5.9 billion partnership w/Lilly from @leilei_wuu Lilly has done dozens of M&A, licensing and collabs in past two years to continue dominating pharma for the long-term endpoints.news/lilly-strikes…

Interesting they at least got a review for MF despite failing on symptoms, something that pelabraisb was not granted. Pelabrsib biggest concern was increased transformation to AML
$KPTIQ Karyopharm FDA Accepts sNDA for XPOVIO (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis PDUFA 06/28/27

“VK2735's retatrutide-like efficacy, tirzepatide-like tolerability, and convenience advantages puts it in a competitive position ahead of 2H27 Ph3 VANQUISH readout."
$VKTX ... Viking Therapeutics: ObesityWeek Supports Best-in-Class Potential -- Oppenheimer (29.22) Analyst Jay Olson commented, "We're encouraged by VK2735's best-in-class potential following VKTX's ObesityWeek event, where 3 leading KOLs identified treatment discontinuation and resulting weight regain as the greatest unmet needs in obesity. VK2735 could uniquely address both through every-other-week and monthly subQ maintenance dosing plus an oral option, which neither tirzepatide nor retatrutide offers. We highlight: 1) maintenance data showing up to 97% weight-loss retention with placebo-like GI tolerability; 2) ~22% weight loss at week 33 with the Ph3 17.5mg dose and no apparent plateau; 3) sustained lipid improvements; 4) a VENTURE analysis showing 74% of patients improved =1 BMI category; and 5) VK3019 primate data supporting amylin combinations. VK2735's retatrutide-like efficacy, tirzepatide-like tolerability, and convenience advantages puts it in a competitive position ahead of 2H27 Ph3 VANQUISH readout."

Robert Pattinson has officially been cast as James Bond. Watch the first teaser for the new 007.

Screw the indexes. This drawdown is already close to 2022 for most stocks.


Also $help placebo arm acted more in line with other MDD trials compared to $DFTX ph3 which had a very low placebo change at week 6 (think close to 5). Clean efficacy and strongest from a phase 3 study in MDD.
$HELP change from baseline at week 6 of 19.5 for the active arm is highest ever in a phase 3 trial for MDD (across mono and adjunctive setting) Price action is 😴

$HELP change from baseline at week 6 of 19.5 for the active arm is highest ever in a phase 3 trial for MDD (across mono and adjunctive setting) Price action is 😴


$CGON congrats to longs (NP)

